19 June 2013 - 19 June 2013 - Canadian biotech group iCo Therapeutics Inc (CVE:ICO) said Tuesday it had finalised the patient enrolment in a Phase II study of its second-generation antisense inhibitor targeting C-raf (ribonucleic acid-mRNA), iCo-007, in diabetic macular oedema (DME).

The trial aims to assess the efficacy and safety after repeated injections of iCo-007 in the patients. The company expects to report results from the primary endpoint of the study in early 2014.

Until now, iCo-007 has demonstrated favourable safety profile with no treatment-related side effects, the firm added.